Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system.

The utilisation of Entresto has been steadily increasing in Ireland since its reimbursement approval. The expenditure in the first year was substantially lower than predicted, and the RAS is an example of how health technology management can facilitate appropriate and cost-effective use of medicines.